Ultragenyx Pharmaceutical (RARE) Total Current Liabilities (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Total Current Liabilities data on file, last reported at $325.0 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 11.43% year-over-year to $325.0 million in Q1 2026; TTM through Mar 2026 was $325.0 million, a 11.43% increase from a year earlier, with the FY2025 full-year figure at $384.0 million, up 11.63% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $325.0 million, down from $384.0 million in the prior quarter.
• Over the last five years, Total Current Liabilities for RARE reached as high as $384.0 million in Q4 2025 and fell as low as $167.2 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $273.8 million across 5 years, with a median of $272.9 million in 2024.
• Across the five-year window, Total Current Liabilities soared 73.64% in 2022 and climbed 7.36% in 2023, its largest moves.
• Year by year, Total Current Liabilities stood at $261.2 million in 2022, then grew by 7.36% to $280.4 million in 2023, then gained by 22.67% to $344.0 million in 2024, then advanced by 11.63% to $384.0 million in 2025, then decreased by 15.36% to $325.0 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $325.0 million in Q1 2026, $384.0 million in Q4 2025, and $340.0 million in Q3 2025.